Scientists at the University of Cambridge, who have been investigating how certain common medications might hold back the movement of cancer cells, have found that daily low-dose aspirin use could curb the spread of certain cancers, including breast and prostate tumors.
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease (KD).
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration (FDA) for use in individuals aged 10 through 25 years.
The U.S. Food and Drug Administration has awarded fast track designation to Adicet Bio’s novel allogeneic gamma delta CAR-T-cell therapy ADI-001 for adults with refractory systemic lupus erythematosus with extrarenal involvement.
A study published in Frontiers in Immunology has found the administration of intravenous immune globulin (IVIG) is associated with a reduction in sepsis mortality and favorable outcomes in laboratory parameters and the functional status, contributing to the ongoing debate on the efficacy of IVIG for sepsis.
The U.S. Food and Drug Administration (FDA) has expanded its approval of Dupixent to chronic obstructive pulmonary disease (COPD).
A study conducted by researchers at Weill Cornell Medicine has demonstrated that a series of six vaccinations containing a modified protein from the surface of HIV particles stimulated initial steps of a potent immune response in young nonhuman primates.
An mRNA vaccine has entered human trials as a treatment for lung cancer. Unlike traditional cancer vaccines such as the HPV vaccine, BNT116 is a therapeutic cancer vaccine designed to reduce tumor growth in patients with cancer or prevent its recurrence. BNT116 contains the genetic code for six molecules frequently seen in non-small cell lung cancers, which make up 80 to 85 percent of lung cancer diagnoses. Exposure to these six molecules primes immune cells to recognize these molecules on cancer cells and eliminate them.
Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million dollar grant from the NIH to advance research in organ transplantation and antibody mediated rejection.
The U.S. Department of Health and Human Services, through the Centers for Medicare and Medicaid Services, has released final guidance outlining the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program.